Indian Immunologicals (IIL) will make drug substances or raw material to make 3-4 million doses of Covid-19 vaccine Covaxin a month now, which will be scale up to 10 million doses a month by December.
IIL and Bharat Biotech International (BBIL), which joined hands in April, have signed four agreements. IIL has repurposed its manufacturing facility in Hyderabad, procured key raw materials and consumables apart from equipment. IIL claimed that these were done at 'breakneck' speed and production commenced in July.
The batches produced at IIL’s manufacturing facility have been tested at BBIL. The yields are more than expected, the company said.
K Anand Kumar, MD, IIL handed over the first lot of Covaxin Drug Substance to Krishna Ella, CMD, Bharat Biotech on August 13, 2021. Kumar said that they received support from the Niti-Aayog, BIRAC, DBT, Mission Covid Suraksha Team, Central and State drug control authorities
Renu Swarup, Secretary, DBT and Chairperson, BIRAC said, ‘’The government has worked relentlessly to provide all possible support for ramping up Covaxin production in the country and speed up Covaxin inoculation drive. The loan license agreement by CDSCO for Indian Immunologicals Ltd to produce Covaxin Drug Substance is a major milestone, achieved in a very short span of time. The DBT-BIRAC support under Mission Covid Suraksha aims to meet the Covid-19 vaccine requirement of our country”.
“IIL is also working on another COVID -19 vaccine and the animal trials are underway currently and is expected to come out by next year for human vaccination," Kumar informed.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU